New Anticoagulants (Dabigatran, Apixaban, Rivaroxaban) for Stroke Prevention in Atrial Fibrillation

被引：6
|
作者：
Aguilar, Maria I. [1 ]
Kuo, Ruth S. [2 ]
Freeman, William D. [3 ,4 ,5 ]
机构：
[1] Mayo Clin, Dept Neurol, Div Cerebrovasc Dis, Phoenix, AZ 85054 USA
[2] Scripps Mem Hosp, Dept Pharm, La Jolla, CA 92037 USA
[3] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA
[4] Mayo Clin, Dept Neurosurg, Jacksonville, FL 32224 USA
[5] Mayo Clin, Dept Crit Care, Jacksonville, FL 32224 USA
来源：
NEUROLOGIC CLINICS | 2013年 / 31卷 / 03期
关键词：
Anticoagulation; Stroke; Atrial fibrillation; Reversal; Direct thrombin inhibitors; Factor Xa inhibitors; Dabigatran; Rivaroxaban; Apixaban; Edoxaban; ORAL ANTICOAGULANTS; RISK STRATIFICATION; WARFARIN; REVERSAL; EFFICACY; SAFETY; CHA(2)DS(2)-VASC; THROMBIN; EDOXABAN; FOCUS;
D O I：
10.1016/j.ncl.2013.03.001
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
New oral anticoagulants have been found to be as efficacious as warfarin and safer in terms of intracranial bleeding. All patients with nonvalvular atrial fibrillation should receive antithrombotic therapy for stroke prevention. For those at low risk, antiplatelet therapy is probably sufficient. For those at intermediate or high risk, anticoagulation is superior to antiplatelet therapy. Four oral anticoagulants are currently approved for stroke and systemic embolism prevention in atrial fibrillation: warfarin, dabigatran, rivaroxaban, and apixaban. Management of bleeding complications while on the new agents remains an area of concern and management is based on anecdotal experience and observational studies.
引用
收藏
页码：659 / +
页数：18
相关论文
共 50 条
  • [41] Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation
    Noseworthy, Peter A.
    Yao, Xiaoxi
    Abraham, Neena S.
    Sangaralingham, Lindsey R.
    McBane, Robert D.
    Shah, Nilay D.
    [J]. CHEST, 2016, 150 (06) : 1302 - 1312
  • [42] Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation
    Sjalander, Sara
    Sjogren, Vilhelm
    Renlund, Henrik
    Norrving, Bo
    Sjalander, Anders
    [J]. THROMBOSIS RESEARCH, 2018, 167 : 113 - 118
  • [43] Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation
    Semeraro, Fabrizio
    Incampo, Francesca
    Ammollo, Concetta T.
    Dellanoce, Claudia
    Paoletti, Oriana
    Testa, Sophie
    Colucci, Mario
    [J]. THROMBOSIS RESEARCH, 2016, 138 : 22 - 29
  • [44] DIRECT COMPARISON OF DABIGATRAN, RIVAROXABAN, AND APIXABAN FOR EFFECTIVENESS AND SAFETY IN NONVALVULAR ATRIAL FIBRILLATION
    Noseworthy, Peter
    Yao, Xiaoxi
    Sangaralingham, Lindsey R.
    Abraham, Neena
    McBane, Robert
    Gersh, Bernard
    Shah, Nilay
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 692 - 692
  • [45] Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
    Chan, Yi-Hsin
    See, Lai-Chu
    Tu, Hui-Tzu
    Yeh, Yung-Hsin
    Chang, Shang-Hung
    Wu, Lung-Sheng
    Lee, Hsin-Fu
    Wang, Chun-Li
    Kuo, Chang-Fu
    Kuo, Chi-Tai
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (08):
  • [46] Novel Oral Anticoagulants in Development: Dabigatran, Rivaroxaban, and Apixaban
    Sattari, Maryam
    Lowenthal, David T.
    [J]. AMERICAN JOURNAL OF THERAPEUTICS, 2011, 18 (04) : 332 - 338
  • [47] Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and Rivaroxaban in atrial fibrillation
    Jansson, M.
    Sjalander, S.
    Sjogren, V.
    Renlund, H.
    Norrving, B.
    Sjalander, A.
    [J]. THROMBOSIS RESEARCH, 2020, 185 : 135 - 141
  • [48] Rivaroxaban, dabigatran and apixaban. New anticoagulants in operative urology [Rivaroxaban, dabigatran und apixaban. Neue antikoagulanzien in der operativen urologie]
    John A.
    Michel M.S.
    [J]. Der Urologe, 2014, 53 (6): : 893 - 903
  • [49] Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
    Yao, Xiaoxi
    Abraham, Neena S.
    Sangaralingham, Lindsey R.
    Bellolio, M. Fernanda
    McBane, Robert D.
    Shah, Nilay D.
    Noseworthy, Peter A.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (06):
  • [50] Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence
    Martinez-Rubio, Antoni
    Andrei Dan, George
    Carlos Kaski, Juan
    [J]. EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2014, 12 (08) : 933 - 947
12345